XGN Relative Valuation
XGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XGN is overvalued; if below, it's undervalued.
Historical Valuation
Exagen Inc (XGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.34. The fair price of Exagen Inc (XGN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.48
Fair
-13.04
PE
1Y
3Y
5Y
Trailing
Forward
-82.03
EV/EBITDA
Exagen Inc. (XGN) has a current EV/EBITDA of -82.03. The 5-year average EV/EBITDA is -13.56. The thresholds are as follows: Strongly Undervalued below -70.95, Undervalued between -70.95 and -42.25, Fairly Valued between 15.13 and -42.25, Overvalued between 15.13 and 43.83, and Strongly Overvalued above 43.83. The current Forward EV/EBITDA of -82.03 falls within the Strongly Undervalued range.
-20.72
EV/EBIT
Exagen Inc. (XGN) has a current EV/EBIT of -20.72. The 5-year average EV/EBIT is -5.44. The thresholds are as follows: Strongly Undervalued below -20.95, Undervalued between -20.95 and -13.20, Fairly Valued between 2.31 and -13.20, Overvalued between 2.31 and 10.06, and Strongly Overvalued above 10.06. The current Forward EV/EBIT of -20.72 falls within the Undervalued range.
2.20
PS
Exagen Inc. (XGN) has a current PS of 2.20. The 5-year average PS is 2.06. The thresholds are as follows: Strongly Undervalued below -0.97, Undervalued between -0.97 and 0.55, Fairly Valued between 3.58 and 0.55, Overvalued between 3.58 and 5.10, and Strongly Overvalued above 5.10. The current Forward PS of 2.20 falls within the Historic Trend Line -Fairly Valued range.
-30.23
P/OCF
Exagen Inc. (XGN) has a current P/OCF of -30.23. The 5-year average P/OCF is -9.37. The thresholds are as follows: Strongly Undervalued below -39.75, Undervalued between -39.75 and -24.56, Fairly Valued between 5.81 and -24.56, Overvalued between 5.81 and 21.00, and Strongly Overvalued above 21.00. The current Forward P/OCF of -30.23 falls within the Undervalued range.
-46.48
P/FCF
Exagen Inc. (XGN) has a current P/FCF of -46.48. The 5-year average P/FCF is -10.19. The thresholds are as follows: Strongly Undervalued below -45.43, Undervalued between -45.43 and -27.81, Fairly Valued between 7.43 and -27.81, Overvalued between 7.43 and 25.04, and Strongly Overvalued above 25.04. The current Forward P/FCF of -46.48 falls within the Strongly Undervalued range.
Exagen Inc (XGN) has a current Price-to-Book (P/B) ratio of 9.03. Compared to its 3-year average P/B ratio of 4.64 , the current P/B ratio is approximately 94.51% higher. Relative to its 5-year average P/B ratio of 3.69, the current P/B ratio is about 145.11% higher. Exagen Inc (XGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -44.40%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -35.96% , the current FCF yield is about -100.00% lower.
9.30
P/B
Median3y
4.64
Median5y
3.69
-6.66
FCF Yield
Median3y
-44.40
Median5y
-35.96
Competitors Valuation Multiple
The average P/S ratio for XGN's competitors is , providing a benchmark for relative valuation. Exagen Inc Corp (XGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 37.87%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XGN increased by 82.68% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.59 to -7.97.
The secondary factor is the Revenue Growth, contributed 37.87%to the performance.
Overall, the performance of XGN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Exagen Inc (XGN) currently overvalued or undervalued?
What is Exagen Inc (XGN) fair value?
How does XGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Exagen Inc (XGN) as of Dec 05 2025?
What is the current FCF Yield for Exagen Inc (XGN) as of Dec 05 2025?
What is the current Forward P/E ratio for Exagen Inc (XGN) as of Dec 05 2025?